Abstract

BackgroundFilgotinib is an oral, selective Janus kinase 1 (JAK1) inhibitor combining a favorable safety profile and clinical efficacy in patients after 4 weeks of dosing with rheumatoid arthritis (RA) with...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Comparison of Pharmacokinetic Parameters of Anagrelide in Healthy Japanese and Caucasian Volunteers
Steven Troy ... Yuzuru Kanakura
Blood | VOL. 120
Steven Troy, et. al.Steven Troy ... Yuzuru Kanakura
16 Nov 2012
Ethnic Sensitivity Study of the Extrafine, Single-Inhaler, Triple Therapy Beclomethasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide Pressurized Metered Dose Inhaler in Japanese and Caucasian Healthy Individuals: A Randomized, Double-Blind, Single-Dose Crossover Study
Massimo Cella ... George Georges
Clinical Therapeutics | VOL. 43
Massimo Cella, et. al.Massimo Cella ... George Georges
29 Sep 2021
Pharmacokinetics of the antiepileptic drug levetiracetam in healthy Japanese and Caucasian volunteers following intravenous administration.
Ayumi Mugitani ... Nathalie Toublanc
European journal of drug metabolism and pharmacokinetics | VOL. 40
Ayumi Mugitani, et. al.Ayumi Mugitani ... Nathalie Toublanc
05 Oct 2014
Comparable Pharmacokinetics and Pharmacodynamics of Melagatran in Japanese and Caucasian Volunteers after Oral Administration of the Direct Thrombin Inhibitor Ximelagatran
Gillis Johnsson ... Anders Bylock
Clinical Pharmacokinetics | VOL. 45
Gillis Johnsson, et. al.Gillis Johnsson ... Anders Bylock
01 Jan 2006
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers